News Snapshot:
(Bloomberg) -- China’s fifth Covid-19 vaccine candidate has entered a phase 3 trial, state media Xinhua News Agency reported. The vaccine, developed by China’s Anhui Zhifei Longcom Biopharmaceutical, will be tested on 5,000 volunteers in Uzbekistan, the report said, citing the Uzbek government. They are between the ages of 18 and 59, and will join the late-stage human trials that are expected to last for a year, Xinhua said. The Anhui-based pharma firm, a subsidiary of listed Chongqing Zhifei Biological Products, received approval from the local authorities last month to produce a coronavirus vaccine. The trial vaccine has been delivered...
